| Notices Forward looking statements Statements contained in these slides about The Medicines Company (the “Company”), the Company's products and product candidates, the timing of clinical trial results, regulatory submissions, product or indication launches, the Company’s future financial and operating results, and future opportunities for the Company, that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "potential", "estimates" , "outlook" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of the Company’s products and, upon approval, its product candidates; the Company’s ability to develop its global operations and penetrate foreign markets; whether the Company's products will advance in the clinical trials process on a timely basis or at all; whether the Company will make regulatory submissions for its products and product candidates on a timely basis; whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, including approvals for Ionsys and for Recothrom in jurisdictions other than the United States and Canada; whether physicians, patients and other key decision makers will accept clinical trial results; risks related to the Company’s dependence on Bristol-Myers Squibb to manufacture and supply Recothrom products during the collaboration term; the Company’s ability to successfully manufacture Recothrom products after it completes the acquisition of the manufacturing assets; the ability of Bristol-Myers Squibb and the Company and Incline and the Company to complete the transactions; the ability of the Company to obtain third-party consents necessary for the transfer of the acquired assets; the ability of the Company to successfully integrate the Recothrom and Incline businesses with its other businesses; the ability of the Company to retain certain key employees in the transactions; the conditions to the completion of the transactions, including the receipt of certain consents required in connection with the transactions that may not be obtained on the terms expected or on the anticipated schedule, including without limitation approval of the transactions under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the transactions; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on November 9, 2012, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements. Non GAAP financial measures The Company believes that presenting the non-GAAP information contained in this presentation assists investors and others in gaining a better understanding of the Company’s core operating results. Management uses this non-GAAP information, in addition to the GAAP information, as the basis for measuring the Company’s core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. Such measures are also used by management in its financial and operating decision-making. Non-GAAP information is not meant to be considered superior to or a substitute for the Company’s results of operations prepared in accordance with GAAP. A reconciliation of non-GAAP measures referred to in this presentation is provided in the Investor Relations section of the Company’s website at www.themedicinescompany.com. |
